StemCell Therapy

DUBLIN--(BUSINESS WIRE)--Jul 15, 2022--

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAm%96 8=@32= 3:@C624E@C >2C<6E C624965 2 G2=F6 @7 &$S d]ec q:==:@? :? a_a`] {@@<:?8 7@CH2C5[ E96 AF3=:D96C 6IA64ED E96 >2C<6E E@ C6249 2 G2=F6 @7 &$S ``]gc q:==:@? 3J a_af[ 6I9:3:E:?8 2 rpv# @7 `b]`eT 5FC:?8 a_a`a_af]k^Am

kAmr@>A2?:6D |6?E:@?65k^Am

kF=mk=:ma>28 pvk^=:mk=:m33:3:@E649 v>3wk^=:mk=:mq:@6?8:?66C:?8 pvk^=:mk=:mtAA6?5@C7 $tk^=:mk=:mv6E:?86 pqk^=:mk=:mx?7@CD pvk^=:mk=:m|6C4< zv2pk^=:mk=:m!2== r@CA@C2E:@? Ws2?296C r@CA@C2E:@?Xk^=:mk=:m$2CE@C:FD pvk^=:mk=:m$@=2C:D q:@E649?@=@8J $C=k^=:mk=:m%96C>@ u:D96C $4:6?E:7:4 x?4]k^=:mk^F=m

kAmz66A:?8 😕 >:?5 E96 F?46CE2:?E:6D @7 r~'xs`h[ H6 2C6 4@?E:?F@FD=J EC24<:?8 2?5 6G2=F2E:?8 E96 5:C64E 2D H6== 2D E96 :?5:C64E :?7=F6?46 @7 E96 A2?56>:4 @? 5:776C6?E 6?5 FD6 D64E@CD] %96D6 :?D:89ED 2C6 :?4=F565 😕 E96 C6A@CE 2D 2 >2;@C >2C<6E 4@?EC:3FE@C]k^Am

kAmp 3:@C624E@C C676CD E@ 2 76C>6?E2E:@? G6DD6=[ H96C6:? 3:@=@8:42= C624E:@?D 2C6 6I64FE65 7@C 56G6=@A:?8 6?KJ>6D 2?5 G2C:@FD @C82?:D>D[ :?4=F5:?8 324E6C:2[ 2?:>2= 46==D 2?5 J62DE[ F?56C 4@?EC@==65 4@?5:E:@?D] xE 2:5D 😕 AC@5F4:?8 D6G6C2= A92C>246FE:42=D[ DF49 2D G244:?6D 2?5 >@?@4=@?2= 2?E:3@5:6D[ >2:?E2:?:?8 E96 :?9@>@86?6@FD DE2E6 @7 E96 46==D E@ @3E2:? E96 56D:C65 @FEAFE[ 2?5 >@?:E@C:?8 E96 6?G:C@?>6?E2= 4@?5:E:@?D 7@C AC@>@E:?8 E96 46== 7@C>2E:@? AC@46DD]k^Am

kAm~? 244@F?E @7 E96D6 AC@A6CE:6D[ 2 3:@C624E@C 😀 6IE6?D:G6=J FD65 3J 3:@A92C>246FE:42= 4@>A2?:6D[ C6D62C49 2?5 56G6=@A>6?E W#U2>AjsX :?DE:EFE:@?D[ 2?5 4@?EC24E C6D62C49 @C82?:K2E:@?D Wr#~DX] pE AC6D6?E[ :E 😀 4@>>6C4:2==J 2G2:=23=6 😕 8=2DD[ DE2:?=6DD DE66=[ 2?5 D:?8=6FD6 >2E6C:2= EJA6D]k^Am

kAm%96 8=@32= 3:@C624E@C >2C<6E :D >2;@C=J 5C:G6? 3J E96 :?4C62D:?8 AC6G2=6?46 @7 G2C:@FD 49C@?:4 5:D62D6D[ DF49 2D 42?46C 2?5 5:236E6D[ 6DA64:2==J 2>@?8DE E96 DE625:=J C:D:?8 86C:2EC:4 A@AF=2E:@?]k^Am

kAmx? =:?6 H:E9 E9:D[ E96 8C@H:?8 ?665 7@C AC6G6?E:G6 G244:?6D[ A2CE:4F=2C=J 5FC:?8 E96 DF556? @FE3C62< @7 E96 4@C@?2G:CFD 5:D62D6 Wr~'xs`hX A2?56>:4[ 92G6 AC@>AE65 D6G6C2= A92C>246FE:42= 4@>A2?:6D E@ 4@?D:56C23=J :?G6DE 😕 C6D62C49 2?5 56G6=@A>6?E W#U2>AjsX 24E:G:E:6D E@ 6IE6?5 E96:C AC@5F4E:@? 42A24:E:6D] %9:D[ 😕 EFC?[ 😀 :?7=2E:?8 E96 @G6C2== D2=6D @7 3:@C624E@CD 24C@DD E96 8=@36]k^Am

kAmp55:E:@?2==J[ D:8?:7:42?E E649?@=@8:42= 25G2?46>6?ED[ DF49 2D E96 :?EC@5F4E:@? @7 D:?8=6FD6 3:@C624E@CD W$&qDX 7@C @AE:>:K:?8 E96 BF2=:EJ[ 7=6I:3:=:EJ[ 2?5 D42=23:=:EJ @7 >:4C@@C82?:D>DV 7@C>2E:@? @A6C2E:@?D H:E9 >:?:>2= 4@DE 2?5 6?6C8J C6BF:C6>6?ED[ 2C6 A@D:E:G6=J DE:>F=2E:?8 E96 >2C<6E 8C@HE9]k^Am

kAmpA2CE 7C@> E9:D[ :?4C62D:?8 3:@A92C>246FE:42=D >2?F724EFC:?8 42A24:E:6D 24C@DD 56G6=@A:?8 ?2E:@?D[ 2=@?8 H:E9 E96 C:D:?8 56>2?5 7@C 3:@C624E@CD E92E DFAA@CE >@56C?[ 6G@=G:?8[ 9:8946== 56?D:EJ[ 2?5 :?E6?D:7:65 4=:?:42= AC@46DD6D C6BF:C:?8 9:89 @IJ86? EC2?D76C 2?5 8C62E 42C3@? 5:@I:56 Wr~aX C6>@G2= 2C6 AC@A6==:?8 E96 >2C<6E 8C@HE9]k^Am

kAm~E96C 724E@CD[ DF49 2D C2A:5 6IA2?D:@? 😕 E96 A92C>246FE:42= 2?5 3:@=@8:4D D64E@CD[ E96 6D42=2E:?8 ?665 7@C 67764E:G6 EC62E>6?E 5CF8D[ 2?5 E96 :?4C62D:?8 2H2C6?6DD 2>@?8 4@?DF>6CD C682C5:?8 E96 7@C>F=2E:@? 2?5 2G2:=23:=:EJ @7 A6CD@?2=:K65 >65:4:?6D[ 2C6 4@?EC:3FE:?8 E@ E96 >2C<6E 8C@HE9 D:8?:7:42?E=J]k^Am

kAmz6J "F6DE:@?D p?DH6C65 😕 %9:D #6A@CEik^Am

kF=mk=:mw@H 92D E96 8=@32= 3:@C624E@C >2C<6E A6C7@C>65 D@ 72C 2?5 9@H H:== :E A6C7@C> 😕 E96 4@>:?8 J62CDnk^=:mk=:m(92E 92D 366? E96 :>A24E @7 r~'xs`h @? E96 8=@32= 3:@C624E@C >2C<6Enk^=:mk=:m(92E 2C6 E96 <6J C68:@?2= >2C<6EDnk^=:mk=:m(92E :D E96 3C622C<6E 32D65 @? E96 EJA6nk^=:mk=:m(92E :D E96 3C622C<6E 32D65 @? E96 FD286nk^=:mk=:m(92E :D E96 3C622C<6E 32D65 @? E96 D42=6nk^=:mk=:m(92E :D E96 3C622C<6E 32D65 @? E96 4@?EC@= EJA6nk^=:mk=:m(92E 2C6 E96 G2C:@FD DE286D :? E96 G2=F6 492:? @7 E96 :?5FDECJnk^=:mk=:m(92E 2C6 E96 <6J 5C:G:?8 724E@CD 2?5 492==6?86D :? E96 :?5FDECJnk^=:mk=:m(92E :D E96 DECF4EFC6 @7 E96 8=@32= 3:@C624E@C >2C<6E 2?5 H9@ 2C6 E96 <6J A=2J6CDnk^=:mk=:m(92E :D E96 568C66 @7 4@>A6E:E:@? 😕 E96 :?5FDECJnk^=:mk^F=m

kAmz6J %@A:4D r@G6C65ik^Am

kAm` !C67246k^Am

kAma $4@A6 2?5 |6E9@5@=@8Jk^Am

kAmb tI64FE:G6 $F>>2CJk^Am

kAmc x?EC@5F4E:@?k^Am

kAmc]` ~G6CG:6Hk^Am

kAmc]a z6J x?5FDECJ %C6?5Dk^Am

kAmd v=@32= q:@C624E@C |2C<6Ek^Am

kAmd]` |2C<6E ~G6CG:6Hk^Am

kAmd]a |2C<6E !6C7@C>2?46k^Am

kAmd]b x>A24E @7 r~'xs`hk^Am

kAmd]c |2C<6E u@C642DEk^Am

kAme |2C<6E qC62

kAmf |2C<6E qC62

kAmg |2C<6E qC62

kAmh |2C<6E qC62

kAm`_ |2C<6E qC62

kAm`` $(~% p?2=JD:Dk^Am

kAm`a '2=F6 r92:? p?2=JD:Dk^Am

kAm`b !@CE6CD u:G6 u@C46D p?2=JD:Dk^Am

kAm`c !C:46 p?2=JD:Dk^Am

kAm`d r@>A6E:E:G6 {2?5D42A6k^Am

kAm`d]` |2C<6E $ECF4EFC6k^Am

kAm`d]a z6J !=2J6CDk^Am

kAm`d]b !C@7:=6D @7 z6J !=2J6CDk^Am

kAmu@C >@C6 :?7@C>2E:@? 23@FE E9:D C6A@CE G:D:E k2 9C67lQ9EEADi^^HHH]C6D62C492?5>2C<6ED]4@>^C6A@CED^de`d_ee^3:@C624E@C>2C<6E8=@32=:?5FDECJEC6?5DD92C6nFE>0D@FC46lq(U2>AjFE>0>65:F>l!C6DD#6=62D6U2>AjFE>04@56lH>A>gCU2>AjFE>042>A2:8?l`faee_`ZZTac``]gZq:==:@?Z(@C=5H:56Zq:@C624E@CZx?5FDECJZE@Za_afZZu62EFC:?8Z$2CE@C:FDTa4Z$@=2C:DZq:@E649?@=@8JZ2?5Z%96C>@Zu:D96CZ$4:6?E:7:4Zp>@?8Z~E96CDU2>AjFE>06I64l;2>FafbAC5Q C6=lQ?@7@==@HQ D92A6lQC64EQm9EEADi^^HHH]C6D62C492?5>2C<6ED]4@>^C^hKbC?6k^2mk^Am

kAm':6H D@FC46 G6CD:@? @? k2 9C67lQ9EEAi^^3FD:?6DDH:C6]4@>Qm3FD:?6DDH:C6]4@>k^2mik2 9C67lQ9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_aa_f`d__d`de^6?^Q C6=lQ?@7@==@HQm9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_aa_f`d__d`de^6?^k^2mk^Am

kAmr~}%pr%i k2 9C67lQ9EEAi^^#6D62C49p?5|2C<6ED]4@>Qm#6D62C49p?5|2C<6ED]4@>k^2mk^Am

kAm{2FC2 (@@5[ $6?:@C !C6DD |2?286Ck^Am

kAmk2 9C67lQ>2:=E@iAC6DDoC6D62C492?5>2C<6ED]4@>QmAC6DDoC6D62C492?5>2C<6ED]4@>k^2mk^Am

kAmu@C t]$]% ~77:46 w@FCD r2== `h`fb___cf_k^Am

kAmu@C &]$]^rp} %@== uC66 r2== `g__daegeb_k^Am

kAmu@C v|% ~77:46 w@FCD r2== Zbdb`c`egh__k^Am

kAmzt*(~#sik^Am

kAmx}s&$%#* zt*(~#si wtp{%w qx~%trw}~{~v*k^Am

kAm$~&#rti #6D62C49 2?5 |2C<6EDk^Am

kAmr@AJC:89E qFD:?6DD (:C6 a_aa]k^Am

kAm!&qi _f^`d^a_aa _cidg p|^sx$ri _f^`d^a_aa _cidg p|k^Am

kAmk2 9C67lQ9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_aa_f`d__d`de^6?Qm9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_aa_f`d__d`de^6?k^2mk^Am

View post:
$11.8 Billion Worldwide Bioreactor Industry to 2027 - Featuring Sartorius, Solaris Biotechnology and Thermo Fisher Scientific Among Others -...

Biotechnology is a wide discipline that harnesses cellular and biomolecular processes to develop technologies that help in improving the health and lives of the people.

Biotechnology is the field that exploits living organisms to make technological advances in various fields for the sustainable development of mankind. It has its applications in the medical as well as agricultural sectors. The biological processes of living organisms have been used for more than 6000 years to make essential products such as bread, cheese, alcohol, etc.

Let us have a look at the various types and applications of biotechnology in various fields.

Also Read: Biotechnology Principles

Biotechnology is divided into the following types:

Medical biotechnology involves the use of living cells to develop technologies for the improvement of human health. It involves the use of these tools to find more efficient ways of maintaining human health. It also helps in the study of DNA to identify the causes of genetic disorders and methods to cure them.

Vaccines and antibiotics have been developed with the help of medical biotechnology that is essential for human health. Several plants are genetically engineered to produce antibodies with the help of biotechnology.

This field deals with the development of genetically modified plants by introducing the gene of interest in the plant. This, in turn, helps in increasing the crop yield.

Various pest-resistant crops such as Bt-cotton and Bt-brinjal are created by transferring the genes from Bacillus thuringiensis into the plants.

The animals with the most desirable characteristics are bred together to obtain the offspring with the desired traits.

Also Read: Biotechnology Principles and Processes

Following are the important applications of biotechnology:

Nutrients can be infused into food in situations of aid. e.g., Golden rice is prepared by the infusion of beta-carotene into the rice.

Biotechnology helps in the production of crops that can handle abiotic stress such as cold, drought, salinity, etc. In the regions with extreme climatic conditions, such crops have proved beneficial in withstanding the harsh climate.

Biotechnology involves the production of alcohol, detergents, cosmetic products, etc. It involves the production of biological elements and cellular structures for numerous purposes.

Spider webs have materials with the strongest tensile strength. The genes from the spiders have been picked up through biotechnological techniques and infused in goats to produce silk proteins in their milk. This helps in the production of silk easily.

Biotechnology is widely used in energy production. Due to the depletion of natural resources, there is a need to find an alternative source. Such fuels are produced by using biotechnology tools. These are environment friendly and do not release any greenhouse gas.

Biotechnology is applied in the development of pharmaceuticals that had proven problematic when produced through conventional means due to purity concerns.

Also Read: Applications Of Biotechnology

This is how biotechnology is a boon to society. To know more about biotechnology class 12 topics such as what is biotechnology, its types and applications, keep visiting BYJUS website or download BYJUS app for further reference.

See original here:
Biotechnology - Types And Applications Of Biotechnology

SUMMARY: Simon Anderson (22) combines advanced physical science and competencies necessary to help people of different backgrounds, capacities, and beliefs.

Simon Anderson is building an Independent Scholars major around disparities in health and healthcare that stem from broader issues of diversity, equity, and inclusion. His major emphasizes coursework in biology and the medical humanities. Simon is also pursuing a degree in Biotechnology, with minors in Honors Interdisciplinary Studies and Pre-Medicine. Simon is a prime example of a Biotech student at JMU--passionate, determined, engaged, and innovative, says Dr. Stephanie Stockwell, past director of the Biotechnology program. By combining a wide array of interests and talents, Simon is paving the way for a lifetime of success and positive impact.

Simon is a graduate of South County High School in Fairfax County, Virginia, where he completed a demanding set of AP courses that nurtured his passions for math, biology, and chemistry. He also participated in the Governors School for Medicine and Health Sciences at Virginia Commonwealth University in the summer of 2017. During this program he worked with other students to examine case studies from three perspectives: Person (in-person interviews with the patient), Scientist (lab tests and results), and Community (implications of the ailment for the surrounding people)before splitting into smaller groups and analyzing a case study from all three perspectives simultaneously. In the area I grew up in, sickness and injury were the main reasons people went to the hospital, not for treatments related to opioid abuse, Simon remembers. But I learned that opioid abuse was also becoming a huge problem. Later, at JMU, he learned about the importance of local and county remote access clinics. Its not just in cities where people lack healthcare services, says Simon. If youre in a rural area you may also not have access.

Simon took a Viral Discovery (ISAT 203) course with ISAT professor Dr. Louise Temple in his freshman semester. In that class, Simon had his first real encounter with laboratory research. Viral Discovery is an exploratory experiential science class designed for incoming freshmen. Students learn about the life cycle and ecology of viruses infecting bacteria, collect soil samples, and practice techniques for isolation and purification of viruses from the soil. Dr. Temple is an expert in bacterial pathogenesis and bacterial virus discovery and genomic analysis. Isolated viruses are visualized in her lab using electron microscopy, and the genomic material is isolated and prepared for nucleic acid sequencing. Dr. Temples class built confidence in my ability to assess a problem and come up with solutions in a setting where theres flexible structure and no right answer, Simon recalls. He wanted to keep on with the work he had invested in phages, and so joined Dr. Temples lab. Simon has learned a number of valuable techniques related to DNA isolation and annotation, and is writing a paper about phages.

More recently, Simon enrolled in Cancer Genetics (BIO 477) with Dr. Tim Bloss, associate professor of biology. The course is cross-listed as a graduate-level course (BIO 577). I really enjoyed learning about how cancer develops and progresses, he says. Learning about molecular malfunctions in cancer helps me think about how I might create and test treatments in the future. Simon notes that Dr. Bloss is gifted at explaining genetics to students at both a basic and advanced level.

Simon is also a teaching assistant for JMUs General Chemistry laboratory courses (CHEM 131L and CHEM 132L). The course is designed to acquaint students with basic procedures and techniques encountered in the chemical laboratory. The experiments illustrate these techniques and supplement lectures. Simon gives instruction to students and assists with in-class procedures. He also digitally comments on students lab plans, data, and reports. It was a difficult, hybrid year of lab instruction due to the COVID pandemic. At first professors filmed experiments in the lab themselves, and then trialed virtual lab simulation software. This spring, Simon and other assistants returned to the labs to teach students. Proper use of pipette filler bulbs is one lesson we teach, notes Simon, People seem to have a lot of trouble with them.

Simon joined Independent Scholars to extend and broaden his undergraduate education. He understood that medical schools want to see students prepare themselves with an education in both science and the humanities. Simon found the Medical Humanities minor in the JMU catalog, and realized that he might build a major around it. Simons major is entitled Social Responsibility in Healthcare. It combines physical science and competencies necessary to help people of different backgrounds, capacities, and beliefs.

I wanted to take more classes across a wider range of subjects, says Simon. The Independent Scholars major made it possible to take a bunch of science courses that built a broader base around medical humanities. Simon hopes that the Independent Scholars major will give him exposure to a little bit of everything:biology, chemistry, bioinformatics, sociology, anthropology, psychology, and philosophy. I am just beginning to realize the connections between everything, he says. I want to understand how my research into biology and chemistry intersects with disparities in healthcare and beyond.

Simon says he likes the Independent Scholars approach to learning: I develop my questions, and then look for courses and experiences that can help me answer those questions. I wanted something different, to choose an area of study where the questions arent well established, or the answers known. Simon has written about the complexities of healthcare for the Independent Scholars e-zine on multiple occasions. In his essays, Simon seeks answers to enduring questions: What does it mean to be a doctor in our globalized world? How do institutions treat people of different backgrounds differently? What is healthy, and who gets to decide what healthy is? What are the impacts of structural and institutional prejudices? he asks. Simon is currently studying and writing about how person-oriented perspectives characterized by a holistic approach to patient management that embraces the physical, psychological, and social aspects of health and disease are becoming essential to undergraduate pre-medical education. His essays may be accessed here.

Independent Scholars students complete a culminating capstone project. Simons project has implications for the mitigation of racial disparities in health. He notes that, despite having roughly equal rates of breast cancer as non-Hispanic white women, African-American women are 40% more likely to die from the disease than white women, experience the highest breast cancer mortality of any racial group, and have an increasing rate of incidence of breast cancer. African American women are also more likely to have hormone-dependent breast cancers, which are deadlier than hormone-independent tumors.

Researchers have shown that delivering the protein HES-1 to hormone-dependent breast cancers has the effect of decreasing a nuclear protein called PCNA (found in dividing cells), which inhibits proliferation of the tumor, explains Simon. Were attempting to show that oxidative stress will prompt production of the GFP encoded behind an hlh-29 promoter to increase green fluorescent protein expression in all cells. If Simons project can provide evidence that oxidative stress is capable of increasing cells levels of proteins like HES-1, then they will have also laid the groundwork for potential clinical applications. One such application could be the induction of localized oxidative stress in tumors in an attempt to stall their proliferation, which would provide other therapies with an opportunity to shrink and kill the cancer.

Simon was a member of JMUs Huber Residential Learning Community (RLC) for freshmen in 2018-2019. The Huber RLC (which no longer operates) required two classes, one in each of the students first semesters. These classes focused on how different fields of medicine coexist, and gave a place for analysis and discussion of the social determinants of health. In the second semester, each student was required to volunteer with health- and education-related services in Rockingham County and Harrisonburg. Simon volunteered with the Virginia Personal Responsibility Education Program Innovative Strategies (VPREIS) project through JMUs Institute for Innovation in Health and Human Services (IIHHS). His volunteer work included working through the units of VPREISs Vision of Youa program for teen sexual and social health education, currently being administered to at-risk youth as part of a randomized controlled study in decreasing teen pregnancy in Virginia. Simon also volunteered at the ECHO (Ecumenical Community Helping Others) food pantry in Springfield, Virginia during the COVID-19 pandemic.

In the summer of 2021, Simon participated in a virtual summer research internship with the Pediatric Oncology Branch of the National Cancer Institute. During the experience, he worked on three projects that identified novel potential molecular targets in neuroblastoma, devised assembly schemes for designing new chimeric antigen receptors, and reviewed transcripts, patient data, and trial design documents for new psychological health programs. He also attended daily interactive seminars on many topics, including pediatric bone and neural cancers, cancer predisposition syndromes, lab mouse genetics, translation of basic science into therapies, and patient advocacy. Outside of the POB, he participated in an immunotherapy journal club, and two workshops on health disparities and social injustice in health research.

Simon also nurtures interests in how things are made. He enjoys watching videos about how the Disney and Universal theme parks create their engineered attractions, and builds models of landmarks and machinery from around the world. In the summer of 2019, Simon taught LEGO Robotics classes to young people in the Fairfax Collegiate Summer Program, based in Herndon.

Visit link:
Health Disparities Research and Biotechnology - JMU - James Madison University

Prophecy Market Insights recently presented Pharmaceutical and Biotechnology market report which provides reliable and sincere insights related to the various segments and sub-segments of the market. The market study throws light on the various factors that are projected to impact the overall dynamics of the Pharmaceutical and Biotechnology market over the forecast period (2019-2029).

The Pharmaceutical and Biotechnology research study contains 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. This Pharmaceutical and Biotechnology market research report estimates the size of the market concerning the information on key retailer revenues, development of the industry by upstream and downstream, industry progress, key highlights related to companies, along with market segments and application. This study also analyzes the market status, market share, growth rate, sales volume, future trends, market drivers, market restraints, revenue generation, opportunities and challenges, risks and entry barriers, sales channels, and distributors.

Base Year

Estimated Year

Forecast Year

2019

2020

2019-2029

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/881

Global Pharmaceutical and Biotechnology market 2020-2030 in-depth study accumulated to supply latest insights concerning acute options. The report contains different predictions associated with Pharmaceutical and Biotechnology market size, revenue, CAGR, consumption, profit margin, price, and different substantial factors. Along with a detailed manufacturing and production analysis, the report also includes the consumption statistics of the industry to inform about Pharmaceutical and Biotechnology market share. The value and consumption analysis comprised in the report helps businesses in determining which strategy will be most helpful in expanding their Pharmaceutical and Biotechnology market size. Information about Pharmaceutical and Biotechnology market traders and distributors, their contact information, import/export and trade analysis, price analysis and comparison is also provided by the report. In addition, the key company profiles/players related with Pharmaceutical and Biotechnology industry are profiled in the research report.

The Pharmaceutical and Biotechnology market is covered with segment analysis and PEST analysis for the market. PEST analysis provides information on a political, economic, social and technological perspective of the macro-environment from Pharmaceutical and Biotechnology market perspective that helps market players understand the factor which can affect businesss accomplishments and performance-related with the particular market segment.

Segmentation Overview:

By Product Type(Vaccines (Recombinant Vaccines, Conventional Vaccines, Recombinant Enzymes, Cell and Gene Therapies and Other Product Types) and Synthetic Immuno-modulators (Cytokines, Interferones, Interleukins and Tumor Necrosis Factor))

By Therapeutic Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Disease Prevention, Cardiovascular Diseases, Neurological Diseases and Other Diseases)

By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

Competitive landscape of the Pharmaceutical and Biotechnology market is given presenting detailed insights into the company profiles including developments such as merges & acquisitions, collaborations, partnerships, new production, expansions, and SWOT analysis.

Pharmaceutical and Biotechnology Market Key Players:

Pfizer

Roche

Johnson-Johnson

Sanofi

Merck, Novartis

Amgen Abbott Laboratories,

Agilent Technologies, Ely Lily

Biogen Scientific

Bio-Rad Laboratories

Danaher, F. Hoffmann-La Roche

Illumina

Merck

PerkinElmer, Qiagen

Thermo Fisher Scientific.

The research scope provides comprehensive market size, and other in-depth market information details such as market growth-supporting factors, restraining factors, trends, opportunities, market risk factors, market competition, product and services, product advancements and up-gradations, regulations overview, strategy analysis, and recent developments for the mentioned forecast period.

The report analyzes various geographical regions like North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa and incorporates clear market definitions, arrangements, producing forms, cost structures, improvement approaches, and plans. Besides, the report provides a key examination of regional market players operating in the specific market and analysis and outcomes related to the target market for more than 20 countries.

Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/881

The report responds to significant inquires while working on Global Pharmaceutical and Biotechnology Market. Some important Questions Answered in Pharmaceutical and Biotechnology Market Report are:

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Pharmaceutical-and-Biotechnology-Market-881

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

See original here:
Regional Strategic Analysis of Pharmaceutical and Biotechnology Market during the Forecasted Period 2020-2030 Construction News Portal - Construction...

The latest research report provides a complete assessment of the Chromatography Resin for Pharmaceuticals & Biotechnology Application Market for the forecast year 2022-2031, which is beneficial for companies regardless of their size and revenue. This Survey report covers the major market insights and industry approach towards COVID-19 (Omicron) in the upcoming years. The Chromatography Resin for Pharmaceuticals & Biotechnology Application Market report presents data and information on the development of the investment structure, technological improvements, market trends and developments, capabilities, and comprehensive information on the key players of the Chromatography Resin for Pharmaceuticals & Biotechnology Application Market. The worldwide market strategies undertaken, with respect to the current and future scenario of the industry, have also been listed in the study.

The report begins with a brief presentation and overview of the Chromatography Resin for Pharmaceuticals & Biotechnology Application Market, about the current market landscape, market trends, major market players, product type, application, and region. It also includes the impact of COVID-19 (Omicron) on the global Chromatography Resin for Pharmaceuticals & Biotechnology Application Market trends, future forecasts, growth opportunities, end-user industries, and market players. It also provides historical data, current market scenario and future insights on Chromatography Resin for Pharmaceuticals & Biotechnology Application Market. This study provides a comprehensive understanding of market value with the product price, demand, gross margin, and supply of the Chromatography Resin for Pharmaceuticals & Biotechnology Application Market. The competitive perspective section of the report presents a clear insight into the market share analysis of the major players in the industry.

See how the research methodology work for the report | request sample report:https://market.us/report/chromatography-resin-for-pharmaceuticals-biotechnology-application-market/request-sample/

*** NOTE: Our team of industry researchers are studying Covid-19 (Omicron) and its impact on the growth of the Chromatography Resin for Pharmaceuticals & Biotechnology Application Market and where necessary we will consider the Covid-19 footmark for better analysis of the market and industries. Contact us cogently for more detailed information.***

Figure:

Competitive Spectrum Top Companies Participating in the Chromatography Resin for Pharmaceuticals & Biotechnology Application Market are:

Mitsubishi CorpThermo Fisher Scientific Inc.Danaher CorporationMerck KGaATosoh CorporationAvantor Inc.Bio-Rad Laboratories Inc.Sartorius Stedim Biotech SAPuroliteBio-Works TechnologiesOthers

Chromatography Resin for Pharmaceuticals & Biotechnology Application Market research report will be sympathetic for:

1. New Investors

2. Propose investors and private equity companies

3. Cautious business organizers and analysts

4. Intelligent network security Suppliers, Manufacturers and Distributors

5. Government and research organizations

6. Speculation / Business Research League

7. End-use industries And much more

Chromatography Resin for Pharmaceuticals & Biotechnology Application Market Segments Evaluated in the Report:

Product Overview:

Based on Product Type

Natural PolymersSynthetic PolymersInorganic Media

Classified Applications of Chromatography Resin for Pharmaceuticals & Biotechnology Application Market :

Based on Technique

Ion Exchange (IEX) ChromatographyAffinity ChromatographyHydrophobic Interaction Chromatography (HIC)Size Exclusion Chromatography (SEC)Multimodal ChromatographyOther Techniques

Do You Have Any Query Or Specific Requirement? Ask Our Industry Expert@https://market.us/report/chromatography-resin-for-pharmaceuticals-biotechnology-application-market/#inquiry

Key regions divided during this report:

The Middle East and Africa Chromatography Resin for Pharmaceuticals & Biotechnology Application Market (Saudi Arabia, United Arab Emirates, Egypt, Nigeria, South Africa)

North America Chromatography Resin for Pharmaceuticals & Biotechnology Application Market (United States, Canada, Mexico)

Asia Pacific Chromatography Resin for Pharmaceuticals & Biotechnology Application Market (China, Japan, Korea, India, Southeast Asia)

South America Chromatography Resin for Pharmaceuticals & Biotechnology Application Market (Brazil, Argentina, Colombia)

Europe Chromatography Resin for Pharmaceuticals & Biotechnology Application Market (Germany, UK, France, Russia, Italy)

The Chromatography Resin for Pharmaceuticals & Biotechnology Application Market research is sourced for experts in both primary and developed statistics and includes qualitative and quantitative details. The analysis is derived Manufacturers experts work around the clock to recognize current circumstances, such as COVID-19, the possible financial reversal, the impact of a trade slowdown, the importance of the limitation on export and import, and all the other factors that may increase or decrease market growth during the forecast period.

TOC Highlights:

Chapter 1. Introduction

The Chromatography Resin for Pharmaceuticals & Biotechnology Application Market research work report covers a brief introduction to the global market. this segment provides opinions of key participants, an audit of Chromatography Resin for Pharmaceuticals & Biotechnology Application Market industry, outlook across key regions, financial services and various challenges faced by Chromatography Resin for Pharmaceuticals & Biotechnology Application Market. This section depends on the Scope of the Study and Report Guidance.

Chapter 2. Outstanding Report Scope

This is the second most important chapter, which covers market segmentation along with a definition of Chromatography Resin for Pharmaceuticals & Biotechnology Application Market. It defines the entire scope of the Chromatography Resin for Pharmaceuticals & Biotechnology Application Market report and the various facets it is describing.

Chapter 3. Market Dynamics and Key Indicators

This chapter includes key dynamics focusing on drivers[ Includes Globally Growing Chromatography Resin for Pharmaceuticals & Biotechnology Application Market Prevalence and Increasing Investments in Chromatography Resin for Pharmaceuticals & Biotechnology Application Market, Key Market Restraints [High Cost of Chromatography Resin for Pharmaceuticals & Biotechnology Application Market], opportunities [Emerging Markets in Developing Countries] and also presented in detail the emerging trends [Consistent Launch of New Screening Products] growth challenges, and influence factors shared in this latest report.

Chapter 4. Type Segments

This Chromatography Resin for Pharmaceuticals & Biotechnology Application Market report shows the market growth for various types of products marketed by the most comprehensive companies.

Chapter 5. Application Segments

The examiners who wrote the report have fully estimated the market potential of key applications and recognized future opportunities.

Chapter 6. Geographic Analysis

Each regional market is carefully scrutinized to understand its current and future growth, development, and demand scenarios for this market.

Chapter 7. Impact of COVID-19(Omicron)Pandemic on Global Chromatography Resin for Pharmaceuticals & Biotechnology Application Market

7.1 North America: Insight On COVID-19 (Omicron) Impact Study 2021

7.2 Europe: Serves Complete Insight On COVID-19 (Omicron) Impact Study 2021

7.3 Asia-Pacific: Potential Impact of COVID-19 (Omicron)

7.4 Rest of the World: Impact Assessment of COVID-19 (Omicron) Pandemic

Chapter 8. Manufacturing Profiles

The major players in the Chromatography Resin for Pharmaceuticals & Biotechnology Application Market are detailed in the report based on their market size, market served, products, applications, regional growth, and other factors.

Chapter 9. Pricing Analysis

This chapter provides price point analysis by region and other forecasts.

Chapter 10. North America Chromatography Resin for Pharmaceuticals & Biotechnology Application Market Analysis

This chapter includes an assessment on Chromatography Resin for Pharmaceuticals & Biotechnology Application Market product sales across major countries of the United States and Canada along with a detailed segmental outlook across these countries for the forecasted period 2022-2031.

Chapter 11. Latin America Chromatography Resin for Pharmaceuticals & Biotechnology Application Market Analysis

Major countries of Brazil, Chile, Peru, Argentina, and Mexico are assessed apropos to the adoption of Chromatography Resin for Pharmaceuticals & Biotechnology Application Market.

Chapter 12. Europe Chromatography Resin for Pharmaceuticals & Biotechnology Application Market Analysis

Market Analysis of Chromatography Resin for Pharmaceuticals & Biotechnology Application Market report includes insights on supply-demand and sales revenue of Chromatography Resin for Pharmaceuticals & Biotechnology Application Market across Germany, France, United Kingdom, Spain, BENELUX, Nordic and Italy.

Chapter 13. Asia Pacific Excluding Japan (APEJ) Chromatography Resin for Pharmaceuticals & Biotechnology Application Market Analysis

Countries of Greater China, ASEAN, India, and Australia & New Zealand are assessed and sales assessment of Chromatography Resin for Pharmaceuticals & Biotechnology Application Market in these countries is covered.

Chapter 14. Middle East and Africa (MEA) Chromatography Resin for Pharmaceuticals & Biotechnology Application Market Analysis

This chapter focuses on Chromatography Resin for Pharmaceuticals & Biotechnology Application Market scenario across GCC countries, Israel, South Africa, and Turkey.

Chapter 15. Research Methodology

The research methodology chapter includes the following main facts,

15.1 Coverage

15.2 Secondary Research

15.3 Primary Research

Chapter 16. Conclusion

Browse Full Report with Facts and Figures of Chromatography Resin for Pharmaceuticals & Biotechnology Application Market Report at:https://market.us/report/chromatography-resin-for-pharmaceuticals-biotechnology-application-market/

Get in Touch with Us :

Mr. Lawrence John

Market.us (Powered By Prudour Pvt. Ltd.)

Send Email:inquiry@market.us

Address:420 Lexington Avenue, Suite 300 New York City, NY 10170, United States

Tel:+1 718 618 4351

Website:https://market.us

Blog:https://techmarketreports.com/

Get More Reports Here:

Enteral Stents Market 2021 Report Explores Key Players Profiles and Sales Data to 2031

Flavonoids Market Study Reveals Size For Emerging Segments by 2031

Automotive Solar Film Market Statistics Based on Facts and Figures, 2022 to 2031

Pour Point Depressant Market Recent Development with Covid-19 Effect Analysis by Top Companies in 2021

Centrifuge Extractors Market Challenges and Opportunities for Stakeholders Focus on Growth Strategies up to 2031

Condenser Fan Motors Market Business Growth based on Expectations and Growth Trends Highlighted Until 2031

L-Lysine Market Objectives of the Study Includes Research Methodology and Assumptions and Forecast by 2031

Safety Glasses Market Growth Key Factors Focus on CAGR Status, Leading Trends, Forecast to 2031

Original post:
Chromatography Resin for Pharmaceuticals & Biotechnology Application Market 2022 Size, Share, Revenue, Growth Opportunities, Trends and Demand by...

SHANGHAI, Jan. 28, 2022 /PRNewswire/ -- HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today announced that it has completed a US$40 million Series A financing to advance the preclinical and clinical development of its series of innovative antibodies and other biologics products. This round of financing was jointly led by OrbiMed and Hankang Capital, followed by Yonghua Investment and Elikon Investment. Before the completion of this round of financing, HanBio was an early product research and development company incubated by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ("Sunshine Guojian"). The company's current pipeline includes three bispecific antibodies in the IND and pre-IND stages, and a variety of early-stage antibodies and other biologics products.

Dr. Zhenping Zhu, Founder, Chairman and Chief Executive Officer of HanBio, said, "We highly appreciate OrbiMed and Hankang Capital and the other investors for their recognition of HanBio's R&D capability, its innovative pipeline and overall development strategy. This round of funds will be used for preclinical research and clinical trials of our multiple antibody and bispecific antibody products, as well as the establishment of an efficient company management and R&D team. We expect to submit IND applications to the regulatory agencies in both China and the United States for three innovative bispecific antibody products in 2022. On the research front we will focus on exploring new therapeutic targets and modalities, and developing innovative medicines with better safety and efficacy profiles to the current standard treatment options."

Dr. Zhu has extensive experience and an excellent track record in the biopharmaceutical industrial field, including more than 28 years of research and management experience in several world-renowned pharmaceutical companies. Prior to founding HanBio, Dr. Zhu served as the President of R&D and Chief Scientific Officer of 3SBio Group. Before joining 3SBio, Dr. Zhu has served as Executive Vice President at Kadmon Holdings, Vice President and Global Head of Protein Sciences at Novartis Biologics, and Vice President of Research at ImClone Systems. Dr. Zhu has contributed greatly to the discovery and development of a number of therapeutic antibody products approved by the US FDA, European EMA and China NMPA; he is the patent inventor of both ramucirumab (CyramzaR) and necitumumab (PortrazzaR), and one of the main contributors to cetuximab (ErbituxR). Dr. Zhu has published more than 200 peer-reviewed scientific papers in international journals, and has applied for or obtained more than 150 patents in China, United States and other international territories.

Dr. Jing Lou, Chairman of Sunshine Guojian, said, "I am very glad that HanBio, as an early product R&D company incubated by Sunshine Guojian, is recognized by leading biotech investors. Sunshine Guojian is committed to working with the investors to fully support HanBio for the rapid development of the company's innovative products that will benefit cancer patients in China and around the world."

Dr. Steven Dasong Wang, Partner at OrbiMed, said, "Dr. Zhu is one of the pioneers and leaders in the global biopharmaceutical industry. Several antibody products he invented or greatly contributed to, including ramucirumab (CyramzaR) and cetuximab (ErbituxR), have become ones of the most prescribed biologics in the treatment of gastric and colorectal cancers, with total global annual sales nearing 3 billion US dollars. HanBio led by Dr. Zhu has impressed us with its holistic approach to target selection, antibody discovery and design, and clinical translation strategy with special focus on cancers of the human digestive system. We look forward to supporting the company in advancing product clinical development and achieving breakthroughs in the treatment of cancers with high prevalence in China."

Mr. Quanhong Yuan, Partner at Hankang Capital, said, "PD1/PDL1 antibodies have reshaped the landscape of cancer treatment, but they also face the problem of limited response rate. Combination therapies and bispecific antibodies represent a new wave of therapeutic modalities, and are expected to provide a breakthrough solution to the treatment of PD1/PD1 resistant tumors. Dr. Zhu and his team at HanBio have rich experience and excellent track record in the field of antibody drug R&D and tumor immunotherapy. We expect HanBio to achieve great success in the field of cancer treatment."

About HanBio Therapeutics

"Transformative Medicines by Innovation."HanBio Therapeutics is an innovative biotechnology company committed to researching and developing next generation transformative medicines to treat patients with serious diseases.

For more information, please contact:Zhenping Zhu, MD, PhDEmail:[emailprotected][emailprotected]

Tel:+1 347 327 0705 (USA) +011 86 186 1234 0399 (China)

SOURCE HanBio Therapeutics

Continue reading here:
HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital - PRNewswire

Biotechnology Reagents Market report offers one of the best solutions to know the trends and opportunities in healthcare industry. The industry analysis report offers broader perspective of the market place with its comprehensive market insights and analysis. This market research report contains lot of features to offer for healthcare industry which includes general market conditions, trends, inclinations, key players, opportunities, and geographical analysis. What is more, global Biotechnology Reagents market document provides superior market perspective in terms of product trends, marketing strategy, future products, new geographical markets, future events, sales strategies, customer actions or behaviors.

The first class Biotechnology Reagents business report contains top to bottom analysis and estimation of various market related factors that are incredibly crucial for better decision making. Competitive analysis has been carried out in this business report for the major players in the market which supports businesses take better moves for enhancing their product and sales. Besides, Biotechnology Reagents market survey report takes into consideration several industry verticals such as company profile, contact details of manufacturer, product specifications, geographical scope, production value, market structures, recent developments, revenue analysis, market shares and possible sales volume of the company.

Download Exclusive Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-biotechnology-reagents-market&AZ

Key Market Players mentioned in this report:Abbott, Agilent Technologies Inc., Danaher, BD, Bio-Rad Laboratories Inc., General Electric, bioMrieux SA, LONZA, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Hoefer, Inc., Meridian Bioscience, Inc., PerkinElmer

Market Analysis and Insights: Global Biotechnology Reagents Market:

The biotechnology reagents market is expected to gain market growth in the forecast period of 2022 to 2027. Data Bridge Market Research analyses that the market is growing with the CAGR of 11.7% in the forecast period of 2022 to 2027 and is expected to reach USD 10.37 billion by 2027. The growing number of clinical trials will help in escalating the growth of the biotechnology reagents market.

This Biotechnology Reagents market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Data Bridge Market Research Biotechnology Reagents market contact us for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

To know more details, visit in depth study Report @ https://www.databridgemarketresearch.com/reports/global-biotechnology-reagents-market?aZ

Biotechnology Reagents Market Country Level Analysis:

The Biotechnology Reagents market is segmented on the basis of product type, application and end user.

The countries covered in the Biotechnology Reagents market report are the U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of the Middle East and Africa (MEA) as a part of the Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Competitive Landscape and Biotechnology Reagents Market Share Analysis:

The Biotechnology Reagents market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to Biotechnology Reagents market.

Table Of Contents: Global Biotechnology Reagents Market

1 Introduction2 Market Segmentation3 Market Overview4 Executive Summary5 Premium Insights6 Global Biotechnology Reagents Market, By Type7 Global Biotechnology Reagents Market, By Tumor Type8 Global Biotechnology Reagents Market, By Application9 Global Biotechnology Reagents Market, By End User10 Global Biotechnology Reagents Market, By Geography11 Global Biotechnology Reagents Market, Company Landscape12 Company Profiles13 Related Reports

Check Complete Table of Contents with List of Table and Figures @ https://www.databridgemarketresearch.com/toc/?dbmr=global-biotechnology-reagents-market&Az

The key questions answered in Biotechnology Reagents Market report are:

Key points covered in the report:

About Us:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email corporatesales@databridgemarketresearch.com

See the rest here:
Biotechnology Reagents Trends, Market Share, Industry Size, Growth, Opportunities and Forecast to 2028 The Oxford Spokesman - The Oxford Spokesman

Highlights

Events and Activities

NIBGE Email

Welcome to NIBGE

PAEC has clear mandates on the safe use of modern sciences with an aim to improve the socio economic growth of the country. NIBGE is one of the main biotechnology institutes of the four bioscience centers of PAEC and was formally inaugurated by the President of Pakistan in 1994. It is also an affiliate center of ICGEB. The institute is a focal point of modern biotechnology and provides a technology receiving unit to help the development of country through applications of modern biotechnology and genetic engineering. The research programs at NIBGE are mainly aimed at improving agriculture, health, environment and industry and are supported by national and international financial grants. The institute research facilities include state of the art equipments supported by technical services, IT facility and a National Library for Biological Sciences. The institute now offers several services and marketable products. The educational programs leading to MPhil and PhD degrees have also been incorporated in the institutes mandate for the development of human resources in modern sciences.

Announcement

Interview Schedule of M.Phil (Biotechnology)

Featured News

Read more here:
Home :: National Institute for Biotechnology and Genetic ...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that investigators presented results from the neratinib arm of the Phase II Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT Trial) at the 2021 Society for Neuro-Oncology Annual Meeting. The presentation, entitled Preliminary results of the neratinib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): a phase II platform trial using Bayesian adaptive randomization, was presented as an oral presentation in the Abstract Session: Clinical Trials II Session. A copy of the presentation is available on the Puma Biotechnology website.

The INSIGhT trial is a multisite investigator-initiated Phase II screening adaptive platform trial where patients with newly diagnosed unmethylated glioblastoma who are IDH R132H mutation negative and with genomic data available for biomarker grouping are eligible. All patients receive radiation therapy and temozolomide and then patients are randomized to receive either adjuvant temozolomide or adjuvant treatment with an experimental agent (neratinib). At the initiation of INSIGhT, three experimental arms, each with a proposed genomic biomarker, are tested simultaneously. Initial randomization is equal across arms. As the trial progresses, randomization probabilities adapt on the basis of accumulating results using Bayesian estimation of the biomarker-specific probability of treatment impact on progression-free survival. Treatment arms were allowed to drop because of low probability of treatment impact on overall survival. The primary endpoint of INSIGhT is overall survival (OS). Progression-free survival (PFS) analysis is used to influence randomization. For the neratinib arm of the trial, patients received 240 mg of neratinib daily as a single agent with mandatory loperamide prophylaxis.

For the neratinib arm of the trial, there were 149 patients in the intent-to-treat population, including 81 patients treated with neratinib and 68 patients in the control arm. For the intent-to-treat population, PFS was not significantly longer (HR 0.75; p=0.12, log rank test) with neratinib (median 6.0 months) versus the control arm (median 4.7 months) and there was no significant improvement in OS (HR 1.01; p=0.75) between neratinib (median 13.8 months) vs. the control arm (median 14.7 months). For patients with activation of the EGFR pathway, defined as patients with either EGFR amplification or mutation, PFS was significantly longer (HR 0.58; p=0.04, log rank test) with neratinib (median 6.3 months) vs. the control arm (median 4.6 months); however, there was no significant improvement in overall survival (HR 0.97; p= 0.94) between neratinib (median 14.4 months) vs. the control arm (median 15.3 months).

Neratinib was generally well tolerated in the trial and toxicities for neratinib were similar to that previously described. For the 81 patients treated with neratinib, there were 6 cases (7.4%) of grade 3 diarrhea and no cases of grade 4 diarrhea. No new toxicity signals were identified in the trial.

Isabel Arrillaga-Romany, MD, PhD, Director of Neuro-Oncology Clinical Trials at Mass General Cancer Center, an investigator on the trial who presented the data at SNO, said, Although preliminary results did not achieve the primary endpoint, subgroup analyses demonstrated improved PFS in patients with EGFR activation and a non-significant trend toward improved overall survival in patients with EGFRVIII mutations, which could warrant further investigation. Additionally, we are very pleased that this trial reinforced feasibility of randomized Bayesian adaptive platform trials for newly diagnosed glioblastoma.

Alan H. Auerbach, Chief Executive Officer and President of Puma, added, We would like to thank the INSIGHT trial investigators and the patients for their participation in the trial. This is the first data demonstrating an effect of neratinib in EGFR amplified or mutated glioblastoma. While we are not looking to pursue further clinical investigations of neratinib in this indication, we are evaluating the potential to develop a backup compound HKI-357, which has preclinically demonstrated better EGFR activity, in this indication.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

IMPORTANT SAFETY INFORMATION

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

The most common adverse reactions (reported in 5% of patients) were as follows:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Lactation: Advise women not to breastfeed.

Please see Full Prescribing Information for additional safety information.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties that could cause Pumas actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on Pumas business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Pumas Annual Report on Form 10-K for the year ended December 31, 2020. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Puma assumes no obligation to update these forward-looking statements, except as required by law.

Originally posted here:
Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting - Business Wire

BOSTON--(BUSINESS WIRE)-- GRO Biosciences Inc. (GRObio), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the hiring of veteran industry executive, Edward Tad Stewart, who joins the team as Chief Business Officer (CBO).

Mr. Stewart has worked extensively in business and corporate development in the biotechnology and pharmaceutical space for more than 20 years. He has played an integral strategic role in scaling platform biotechnology companies from early stages through FDA-approval and product launch. Mr. Stewart served most recently as Chief Business Officer of Ribon Therapeutics. Prior to his role at Ribon he served as President and CEO of Commense, Inc., Chief Business Officer of Crescendo Biologics, and spent many years with Merrimack Pharmaceuticals in various roles, including SVP of Business Development and Head of Commercial. Mr. Stewart received his MBA from Cornell University.

We are thrilled to have Tad join our executive team. His deep experience in business development and transactions will be instrumental to our partnering activities, and his expertise in product development will accelerate our commercialization efforts, said Daniel J. Mandell, PhD, Co-Founder and Chief Executive Officer of GRO Biosciences. Tad is an established leader in biotechnology, and his unique combination of transactional and strategic savvy will be a great asset to GRObio as we continue to advance our platform and pipeline.

About GRO Biosciences

GRO Biosciences (GRObio) is leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics. The Company is transforming treatments for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases to improve the lives of patients. GRObio is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique NSAA (non-standard amino acid) chemistries. The Companys NSAA therapeutics feature previously unattainable capabilities including unprecedented duration of action and precise regulation of the immune system. GRObio, co-founded by George Church, PhD of Harvard Medical School in 2016, is headquartered in Cambridge, MA. Find GRObio on LinkedIn, Twitter, Instagram, Facebook and the web at grobio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005427/en/

Read more from the original source:
GRO Biosciences Strengthens Management Team With Appointment of Veteran Biotechnology Executive, Edward Stewart as Chief Business Officer - BioSpace

Polymerase Chain Reaction (PCR) Sales to Surpass US$ 12 Bn through 2031 as Adoption of Real-Time PCR Surges amid COVID-19

Fact.MRs latest study discusses factors affecting the polymerase chain reaction (PCR) market growth. It provides in-depth analysis of various market segments, including product and end user across seven major regions. The report further profiles leading PCR manufacturers and examines the effect of their growth strategies on the global market.

Fact.MR A Market Research and Competitive Intelligence Provider: According to the latest Fact.MR analysis, the global polymerase chain reaction (PCR) market will reach US$ 3.6 Bn by the end of 2021. Owing to the surging demand for PCR products, the overall market is projected to register growth at 10% CAGR between 2021 and 2031.

Sales in the PCR market are expected to increase with rising prevalence of target diseases and genetic disorders. Also, factors such as growing popularity of portable PCR testing kits, advancements in PCR technology, and increasing government funding for research activities will facilitate the growth in the market.

PCR has emerged as an ideal technique for the amplification of DNA sequences. It is a simple and cost-effective technique which produces results rapidly. It is an extensively used technique in medical laboratory research for a wide range of applications including biomedical research and criminal forensics.

The unprecedented outbreak of COVID-19 had a positive impact on the PCR market. It created huge demand for reliable and rapid detection techniques such as RT-PCR. Various companies also launched novel PCR test kits for the detection of virus.

Also, RT-PCR emerged as an ideal technique for detection of COVID-19 virus. It is significantly faster and has lower risk of contamination or errors.

Request a report sample to gain compressive insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4861

As per Fact.MR analysis, PCR reagents will account for around 60% of total PCR market revenue by 2031. Rising demand for diagnostic tests and launch of new reagents specific to the test type are some key factors accelerating the demand for reagents used in polymerase chain reaction. Furthermore, RT PCR systems market to witness significant growth.

Regionally, North America will continue to dominate the PCR market, owing to the presence of a well-established healthcare infrastructure, continuous advances in clinical research, and high prevalence of genetic disorders such as Klinefelter's syndrome and Down syndrome. The region is poised to expand at a healthy growth rate of 7.5% annually.

However, Asia is projected to register the fastest growth on the back of increasing penetration of PCR products, rising government support, high prevalence of chronic diseases, and expanding healthcare infrastructure.

As the demand for PCR continues to rise, leading manufacturers are moving towards developing portable micro-scale devices. They also are introducing advanced PCR instruments, reagents and consumable that will allow quick nucleic acid amplification. This is expected to create growth opportunities for the market, says a Fact.MR analyst

Key Takeaways from Polymerase Chain Reaction Market Survey

Key Drivers

Key Restraints

To gain in-depth insights on Polymerase Chain Reaction Market, request methodology at

https://www.factmr.com/connectus/sample?flag=RM&rep_id=4861

Competitive Landscape

Key players operating in the polymerase chain reaction market are embracing advanced technologies for the development of new products. They have adopted various strategies such as mergers, partnerships, collaborations and manufacturing of advanced portable PCR products to increase their sales.

Some of the prominent players operating in the polymerase chain reaction market profiled by Fact.MR are:

More Insights on the Global Polymerase Chain Reaction Sales Outlook

Fact.MR provides an incisive coverage on global polymerase chain reaction market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global demand for polymerase chain reaction with a detailed segmentation on the basis of:

Key Questions Covered in the Polymerase Chain Reaction Market Outlook Report

Explore Fact.MRs Coverage on the Healthcare Domain

Rapid Medical Diagnostic Kits Market- Infectious disease incidence has been steadily increasing over the last few decades, driving up demand for rapid medical diagnostic kits around the world. The need to detect novel pathogens that cause diseases is propelling the market forward. The low cost of rapid medical diagnostic kits is propelling market growth. Blood glucose testing is in high demand, and it has been growing at the quickest rate of all types of tests across all geographies. Technology advancements and strategic alliances by key market players have paved the way for rapid medical diagnostic kit innovations.

COVID-19 Saliva-based Detection Kits- COVID-19 detection treatments are likely to be in high demand due to the availability of COVID-19 virus variants and the continued danger of infection. Manufacturers are focusing on delivering cost-effective and convenient testing solutions as COVID-19 diagnostics become more widely employed. While vaccination initiatives have reduced the incidence rate in some nations, the virus continues to represent a serious concern and has a high occurrence rate due to mutant forms. Future viral mutant strains, as well as increased knowledge of COVID-19 testing, are predicted to maintain market growth.

PCR and Real-time PCR Molecular Diagnostics Market - The COVID-19 pandemic has boosted prospects for the growth of the PCR and real-time PCR molecular diagnostics market. Real-time (qPCR) and digital (dPCR) PCR tests have been used in a variety of healthcare settings to detect and diagnose potential cases. Because of its high sensitivity, healthcare providers have embraced PCR tests on a large scale. As a result of such trends, the global PCR and real-time PCR molecular diagnostics market is poised to soar to new heights, surpassing a significant revenue threshold in the coming decade.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making.

MarketNgage is powered by Fact.MR our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.

You can access all our healthcare research reports by signing up with MarketNgagesMarket Research Subscriptionwith FREE credits. MarketNgage is powered by Fact.MR A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.

Contact:

Mahendra SinghUS Sales Office11140 Rockville PikeSuite 400Rockville, MD 20852United StatesTel: +1 (628) 251-1583E: sales@factmr.com

Source: Fact.MR

Continue reading here:
Polymerase Chain Reaction (PCR) Market to Expand by 3.3x as Application in Pharmaceutical & Biotechnology Industry Grows - BioSpace

Northampton, MA --News Direct-- Illumina

Were honored to be named to the prestigious 2021 Dow Jones Sustainability Indices for a third year in a row. Illumina received the highest score in the Pharmaceuticals, Biotechnology and Life Sciences industry.

Inclusion in the DJSI highlights our commitment to continuously improving and growing our Corporate Social Responsibility (CSR) program to build a more sustainable and equitable future for all. Our program focuses on accelerating access to genomics, supporting our communities, and integrating environmental stewardship into our operations.

If you would like to hear more about our CSR program, join us at our inaugural ESG Investor event on Tuesday Nov 16 at 11 am PT.

Thank you to all our employees for championing the needs of patients, customers, our communities, and our planet.

View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com

View source version on newsdirect.com: https://newsdirect.com/news/illumina-named-to-2021-dow-jones-sustainability-indices-with-highest-score-in-pharmaceuticals-biotechnology-and-life-sciences-industry-107725996

Excerpt from:
Illumina Named to 2021 Dow Jones Sustainability Indices With Highest Score in Pharmaceuticals, Biotechnology and Life Sciences Industry - Yahoo...

The report on Global Food Biotechnology Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition of the product or service studied in the report. Along with this, it also contains a summary of the main applications of this product or service in various industrial sectors. In addition, market research experts have also provided information on the manufacture or production of the product or service and its distribution strategy.

Other important factors studied in the global Food Biotechnology market report include demand and supply dynamics, industrial processes, import and export scenarios, R&D development activities and cost structures. In addition, this report also calculates figures for demand and supply for consumption, production cost, gross profit margins and sales price for products.

Get FREE Sample copy of this Report with Graphs and Charts at:https://reportsglobe.com/download-sample/?rid=289972

The segmentation chapters enable readers to understand aspects of the market such as its products, available technology and applications. These chapters are written to describe their development over the years and the course they are likely to take in the coming years. The research report also provides detailed information on new trends that may define the development of these segments in the coming years.

Food Biotechnology Market Segmentation:

Food Biotechnology Market, By Application (2016-2027)

Food Biotechnology Market, By Product (2016-2027)

Major Players Operating in the Food Biotechnology Market:

Company Profiles This is a very important section of the report that contains accurate and detailed profiles for the major players in the global Food Biotechnology market. It provides information on the main business, markets, gross margin, revenue, price, production and other factors that define the market development of the players studied in the Food Biotechnology market report.

Global Food Biotechnology Market: Regional Segments

The different section on regional segmentation gives the regional aspects of the worldwide Food Biotechnology market. This chapter describes the regulatory structure that is likely to impact the complete market. It highlights the political landscape in the market and predicts its influence on the Food Biotechnology market globally.

Get up to 50% discount on this report at:https://reportsglobe.com/ask-for-discount/?rid=289972

The Study Objectives are:

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Food Biotechnology market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

Some Major Points from Table of Contents:

Chapter 1. Research Methodology & Data Sources

Chapter 2. Executive Summary

Chapter 3. Food Biotechnology Market: Industry Analysis

Chapter 4. Food Biotechnology Market: Product Insights

Chapter 5. Food Biotechnology Market: Application Insights

Chapter 6. Food Biotechnology Market: Regional Insights

Chapter 7. Food Biotechnology Market: Competitive Landscape

Ask your queries regarding customization at: https://reportsglobe.com/need-customization/?rid=289972

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Website: Reportsglobe.com

Original post:
Food Biotechnology Market 2021 Detailed Analysis of top Ventures with Regional Outlook | Key Companies: ABS Global, Arcadia Biosciences, AquaBounty...

The market has been high on Cellect Biotechnology Ltd - ADR (APOP) stock recently. APOP gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.

InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.

Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

Cellect Biotechnology Ltd - ADR (APOP) stock is trading at $4.17 as of 12:27 PM on Thursday, Feb 11, a decline of -$0.58, or -12.19% from the previous closing price of $4.75. The stock has traded between $3.92 and $4.70 so far today. Volume today is elevated. So far 667,963 shares have traded compared to average volume of 237,549 shares.

To see InvestorsObserver's Sentiment Score for Cellect Biotechnology Ltd - ADR click here.

Cellect Biotechnology Ltd is a biotechnology company that has developed a novel technology platform known as ApoGraft that functionally selects cells in order to improve the safety and efficacy of regenerative medicine and cell therapies. The company is developing its first product based on its ApoGraft technology platform, the ApoTainer kit that utilizes FasL- apoptotic protein.

Click Here to get the full Stock Score Report on Cellect Biotechnology Ltd - ADR (APOP) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read more here:
Is Cellect Biotechnology Ltd - ADR (APOP) a Stock to Watch This Week? - InvestorsObserver

Lineage Cell Therapeutics Inc (LCTX) is near the top in its industry group according to InvestorsObserver. LCTX gets an overall rating of 81. That means it scores higher than 81 percent of stocks. Lineage Cell Therapeutics Inc gets a 95 rank in the Biotechnology industry. Biotechnology is number 16 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 81 would rank higher than 81 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Lineage Cell Therapeutics Inc (LCTX) stock is trading at $2.96 as of 3:02 PM on Friday, Feb 12, an increase of $0.13, or 4.59% from the previous closing price of $2.83. The stock has traded between $2.79 and $3.05 so far today. Volume today is 2,543,347 compared to average volume of 2,141,025.

Click Here to get the full Stock Score Report on Lineage Cell Therapeutics Inc (LCTX) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the original post:
Is Lineage Cell Therapeutics Inc (LCTX) The Right Choice in Biotechnology? - InvestorsObserver

Xeris Pharmaceuticals Inc (XERS) is near the top in its industry group according to InvestorsObserver. XERS gets an overall rating of 78. That means it scores higher than 78 percent of stocks. Xeris Pharmaceuticals Inc gets a 92 rank in the Biotechnology industry. Biotechnology is number 16 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 78 would rank higher than 78 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Xeris Pharmaceuticals Inc (XERS) stock has gained 7.47% while the S&P 500 has fallen 0% as of 10:19 AM on Friday, Feb 12. XERS is higher by $0.49 from the previous closing price of $6.63 on volume of 4,496,742 shares. Over the past year the S&P 500 is up 16.07% while XERS is higher by 72.64%. XERS lost -$3.10 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Xeris Pharmaceuticals Inc (XERS) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Continued here:
Is Xeris Pharmaceuticals Inc (XERS) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Artelo Biosciences Inc (ARTL) is around the top of the Biotechnology industry according to InvestorsObserver. ARTL received an overall rating of 73, which means that it scores higher than 73 percent of all stocks. Artelo Biosciences Inc also achieved a score of 89 in the Biotechnology industry, putting it above 89 percent of Biotechnology stocks. Biotechnology is ranked 16 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Artelo Biosciences Inc (ARTL) stock is trading at $3.06 as of 10:19 AM on Friday, Feb 12, a gain of $1.43, or 87.73% from the previous closing price of $1.63. The stock has traded between $2.62 and $3.67 so far today. Volume today is elevated. So far 111,532,303 shares have traded compared to average volume of 7,246,523 shares.

Click Here to get the full Stock Score Report on Artelo Biosciences Inc (ARTL) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

More here:
Is Artelo Biosciences Inc (ARTL) the Top Pick in the Biotechnology Industry? - InvestorsObserver

In recent years, however, producers of grapefruit-flavored foods and drinks have not had it easy. Figures from the US Department of Agriculture tell the tale: In the winter of 199697, Florida farmers harvested 59 million boxes of grapefruit. This season, the forecast is for a mere 4.6 million boxes.

Worldwide, the production of grapefruit and other citrus is in peril because of the spread of the citrus greening disease, as well as temperature shifts and extreme weather caused by climate change. Meanwhile, demand for natural citrus flavoring has gone through the roof.

Marifaith Hackett, director of specialty chemicals for the consulting firm IHS Markit: When ingredients come out of by-products of something else, there is always the danger that supply and demand are really out of whack. If you are a purchasing manager, youre likely thinking, We just have to come up with something better.

In the flavor and fragrance industry, that something better may be a manufacturing platform based on fermentation using modified microbes.

Top flavor and fragrance companies have been quietly partnering with biotechnology firms for as long as 2 decades. Recently, their interest has become more public, thanks to acquisitions and in-house investments by firms such as BASF, Firmenich, Givaudan, and Takasago International. And biotech entrants, including Conagen and Manus Bio, are at work expanding the list of available molecules.

Click here to read the full article.

Photo source: Dreamstime.com

See original here:
Flavor and fragrance industries are embracing biotechnology - FreshPlaza.com

Autolus Therapeutics PLC (AUTL) is around the bottom of the Biotechnology industry according to InvestorsObserver. AUTL received an overall rating of 34, which means that it scores higher than 34 percent of all stocks. Autolus Therapeutics PLC also achieved a score of 23 in the Biotechnology industry, putting it above 23 percent of Biotechnology stocks. Biotechnology is ranked 16 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Autolus Therapeutics PLC (AUTL) stock is trading at $7.60 as of 11:19 AM on Friday, Feb 12, an increase of $0.46, or 6.5% from the previous closing price of $7.14. The stock has traded between $7.04 and $7.70 so far today. Volume today is high. So far 1,529,581 shares have traded compared to average volume of 657,454 shares.

Click Here to get the full Stock Score Report on Autolus Therapeutics PLC (AUTL) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See the rest here:
Should You Buy Autolus Therapeutics PLC (AUTL) in Biotechnology Industry? - InvestorsObserver

The 48 rating InvestorsObserver gives to AgeX Therapeutics Inc (AGE) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 46 percent of stocks in the Biotechnology industry, AGEs 48 overall rating means the stock scores better than 48 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

AgeX Therapeutics Inc (AGE) stock has risen 22.5% while the S&P 500 has fallen -0.2% as of 11:50 AM on Wednesday, Feb 10. AGE is higher by $0.54 from the previous closing price of $2.40 on volume of 416,032 shares. Over the past year the S&P 500 is up 16.26% while AGE is higher by 124.43%. AGE lost -$0.30 per share the over the last 12 months.

Click Here to get the full Stock Score Report on AgeX Therapeutics Inc (AGE) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the original post:
Is AgeX Therapeutics Inc (AGE) the Top Pick in the Biotechnology Industry? - InvestorsObserver